Boston Scientific Corp. has acquired private firm and maker of FDA-approved fallopian tube cell collection device, Nvision Medical Corp., in a deal worth $275 million. The sale will include a $150 million cash payment and up to $125 million in clinical and commercial milestone payments across the next four years. The acquisition is not expected to impact Boston Scientific's bottom line through 2018 and 2019.

Loxo Oncology Inc. and Illumina Inc. have struck up a strategic partnership to develop and commercially launch a multigene panel companion diagnostic (Cdx) for broad tumor profiling. The next-generation sequencing (NGS) diagnostic would carry a pan-cancer indication. The companies plan to pursue an approval for a variation of Illumina's Trusight Tumor 170 along with Loxo Oncology's therapies, larotrectinib and Loxo-292, which affect NTRK gene fusions and RET gene alterations, respectively.

Medtronic plc has received FDA IDE approval for a pivotal study of its Symplicity Spyral renal denervation (RDN) system in treatment of patients with hypertension. The trial, SPYRAL HTN, is being conducted as part of the firm's multi-phase Spyral HTN global clinical program, which seeks to evaluate the efficacy and safety of its RDN platform. Minimally invasive RDN procedures impact nerves in the kidney that regulate blood pressure, intending to decrease pressure among hypertensive patients. Symplicity Spyral is approved in 50 countries and is an investigational device in Japan and the U.S.